Redeye updates its estimates and valuation after Boreo’s Q4 2025 report.
* Solid earnings momentum in Paving services * Divestment brings net cash position and dividend * M&...
Redeye provides an update following Truecaller’s Q4 2025 report, which aligned with preliminary figu...
Redeye comments on Camurus' Q4 report 2025, which was below our estimates due to a large sequential ...
Catella's shares fell 14% following Q4 results, driven by investor disappointment over the SEK0.
* EEs down 16% to 2.6m, SEK 4.6m installations, EBIT 7% above us * Opex, market and installation tai...
* Annual revenue exceeds MSEK 200 * The bottom line disappoints in Q4 * We keep our fair value of SE...
Redeye provides an initial comment on Scandinavian ChemoTech’s Q4 2025 report.
Redeye provides an initial take following the release of Corline’s Q4 2025 report.
Aspo has EBITA improvement potential also this year as Telko and lower group costs contribute, but a...
Redeye views Catella's Q4 2025 results as broadly reassuring.
Redeye comments on SHH’s Q4 2025 report, which landed relatively in-line with the company’s prelimin...
Redeye shares its initial view on Modelon’s Q4 2025 report, which was softer than expected regarding...
Redeye provides its initial take on Moberg Pharma’s Q4 report, where sales greatly exceeded our expe...
Truecaller’s Q4 results align with its preliminary figures, highlighted by a significant margin beat...
* Q4 EBIT of SEK 11m, way below expectations driven by a SEK 151 impairment * Underlying Corporate F...
After a year marked by both progress and setbacks, Xspray enters a pivotal 2026, with two upcoming P...
* EBIT SEK 2m vs FactSet consensus 12m * Sales declined 9% in USD terms, and DPS cut to SEK 2 (8) * ...
Redeye comments on G5’s Q4-resulst which were weaker than expected driven by a soft topline, partly ...
G5's Q4 report looks soft, driven by 5% weaker-than-expected top line which filters through to earni...
